ASCO 2025 | Development of TB707, an inhaled gene therapy delivering IL-2 & IL-12 to the TME
Wen Wee Ma, MBBS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, comments on TB707, a novel gene therapy treatment which utilizes non-replicative herpes simplex virus to deliver genes encoding IL-2 and IL-12, delivering high levels of the cytokines locally to the tumor environment (TME) through inhalation. The method has shown promise in treating advanced solid tumors with lung predominant disease and is designed to minimize systemic cytokine release syndrome. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
TB707 is a novel gene therapy treatment that is utilizing non-replicative herpes simplex virus to deliver genes encoding IL-2 and IL-12. So IL-2 and IL-12 when it’s given by a systemic route like IV, you can produce quite a bit of cytokine release syndrome that can limit the efficacy of this treatment. So what it’s designed to do is actually to administer locally to deliver a high amount of IL-2 and IL-12 to the local tumor environment...
TB707 is a novel gene therapy treatment that is utilizing non-replicative herpes simplex virus to deliver genes encoding IL-2 and IL-12. So IL-2 and IL-12 when it’s given by a systemic route like IV, you can produce quite a bit of cytokine release syndrome that can limit the efficacy of this treatment. So what it’s designed to do is actually to administer locally to deliver a high amount of IL-2 and IL-12 to the local tumor environment. In this particular study, what’s special about it is that we are actually administering by inhalation. So patients with advanced solid tumor with lung predominant disease will be breathing in the TB707 using an off-the-shelf nebulizer.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
